Symmetry Investments LP Buys Shares of 28,800 Kenvue Inc. (NYSE:KVUE)

Symmetry Investments LP bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, HoldingsChannel reports. The firm bought 28,800 shares of the company’s stock, valued at approximately $524,000.

Several other institutional investors have also added to or reduced their stakes in KVUE. Manchester Capital Management LLC boosted its stake in Kenvue by 80.8% during the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares during the last quarter. Mather Group LLC. purchased a new stake in Kenvue during the 1st quarter valued at $28,000. Riverview Trust Co purchased a new stake in Kenvue during the 1st quarter valued at $33,000. MV Capital Management Inc. boosted its stake in Kenvue by 71.2% during the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after purchasing an additional 642 shares during the last quarter. Finally, Salomon & Ludwin LLC bought a new position in shares of Kenvue during the 1st quarter valued at $33,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on KVUE shares. JPMorgan Chase & Co. increased their price target on Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Citigroup lowered their price target on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of Kenvue in a report on Wednesday, August 7th. UBS Group increased their price target on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $21.44.

Kenvue Price Performance

Shares of Kenvue stock opened at $23.02 on Friday. Kenvue Inc. has a one year low of $17.67 and a one year high of $23.55. The stock’s fifty day moving average is $20.92 and its 200 day moving average is $19.96. The stock has a market cap of $44.08 billion, a P/E ratio of 29.51, a P/E/G ratio of 2.92 and a beta of 1.40. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. The business had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business’s quarterly revenue was down .3% on a year-over-year basis. During the same period last year, the firm earned $0.32 earnings per share. Sell-side analysts anticipate that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were given a dividend of $0.205 per share. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date was Wednesday, August 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.56%. Kenvue’s dividend payout ratio (DPR) is presently 105.13%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.